Paid Clinical Trials - 82,000 Members & Growing

  • Sponsored Links
  • About Us
  • Auto-Updates
  • FAQ's
  • Quick Start Guide
www.GlobalTestMarket.com

 

Find Paid Clinical Trials Join Paid Clinical Trials ...

PaidClinicalTrials.org is a registry of compensated and uncompensated, federally and privately supported clinical trials conducted in the United States and around the world. Here you will find information about a trial's purpose, who may participate, locations, and phone numbers.

 

Find Paid Clinical Trials Clinical Trial Seekers - PCT is a public service, sponsor supported, clinical trial database that may be accessed by the general public at no charge in accordance with our terms of service use.

Clinical trials are added and removed each day on a 30 day rotation. For accuracy - We only list clinical trials that have been reported to these government agencies in the last 30 days:

 

U.S. National Library of Medicine,
U.S. Department of Health & Human Services
U.S. National Institutes of health Services.







Paid Clinical Trials - Auto Update Service

If you would like to receive timely and important notifications about new clinical trials in your area please fill out this short form. There is never any cost for our notification services. We value your privacy, your email address and member information is NEVER shared!

*  Your Email Address:
*  Preferred Format:
    Title:
    First Name:
    Country:
    State (US):
    City (UK):
    Territory (AU):

Tips for Finding Clinical Trials

 

One of the toughest and most-time consuming parts for medical research staff conducting the clinical trials is actually finding volunteers willing to participate. Research staff are looking for you! There are numerous ways to identify clinical trials looking for healthy human volunteers.

 

Trials are actively conducted by hospitals, universities, foundations, and contract research organizations (CROs, firms that conduct studies for big pharmaceutical and biotechnology companies). According to CISCRP, nearly 40% of these clinical trials can be learned about through media such as tv, radio, or printed ads. While finding studies through tv and radio ads might be difficult, you can actively scour the wanted section of your local newspapers to find trials.

Most local research clinics run ads for volunteers in the local newspaper, employment papers, on TV, and on the radio. They also post ads on Craigslist and on their own websites. Call them up as soon as you see something of interest. If the study is no longer recruiting volunteers, they might enter you in there database for future study participation.

 

Look up local research clinics in your phone book and ask (a) if they have any studies openly recruiting healthy volunteers and (b) if you could be entered into their volunteer database.

College campuses and major universities with research hospitals are also great places to find clinical trial. Schools of medicine, dentistry, and nursing, along with departments of psychology, sociology, and communications, at local universities, are always looking for willing volunteers for their experiments. Perform an internet search for the hospitals, schools, and departments on nearby campuses, then look for any section concerning clinical trials or research volunteers.


When searching for clinical trials on our website you will click on a Clinical Trial Information sheet like this example. Find Paid Clinical Trials Example Information Sheet. The first thing you should do is to see if the clinical trial is right for you. You can do this by quickly scanning the headings of the information sheet. These headings are highlighted on the left by blue icons as follows:


  >> Status of the Clinical Trial (This will appear at the top in red or green)


Purpose - This will briefly let you know about the clinical trial and how it is conducted.


Eligibility - This tells you age, gender and health status information. If you do not meet these eligibility requirement you should move to another clinical trial.


Contacts and Locations - This will list the locations the clinical trial is being conducted and it will usually list the contact person to call. Note - Even if your location is not listed you should call the clinical trial investigator. Sometimes their locations have not been updated or they are willing to pay time and travel expenses.


More Information - This will often give alternative contact people and other pertinent information about the trial.

These headings appear on the left side of the information sheet and are fairly self explanatory. Doing this will help you to quickly evaluate if the clinical trial is right for you.

 


 

Paid Clinical Trials Searching Tips

 

Paid Clinical Trials Check the Conditions Category - If you only search the "Locations" directory you are missing out on a lot of clinical trials. Trials that are listed by "Condition" usually have multiple locations and can add new locations as the study moves forward.

 

Paid Clinical Trials Register Your Profile with us. - You can post your location and condition in our personal clinical trials directory for FREE. This helps the research recruiters find you when the right trial becomes available. Register for Clinical Trials Here.

 

Paid Clinical Trials Call the Clinical Trial Recruiters - At the bottom of all the information sheets you will see a "Contact Information" heading. Many clinical trials can be conducted in remote locations and the recruiters can help you.

 

Paid Clinical Trials Subscribe to our Auto Update Service - By subscribing to our Auto Update Service you will receive automated emails informing you when new trials have opened in your area.


Browse Locations ... United States» ... New York» ... Buffalo







  • Condition:   Ischemic Stroke
    Interventions:   Biological: 3K3A-APC;   Drug: Placebo
    Sponsors:   ZZ Biotech, LLC;   National Institute of Neurological Disorders and Stroke (NINDS);   Cedars-Sinai Medical Center;   Massachusetts General Hospital;   University of Iowa
    Not yet recruiting - verified August 2014

  • Conditions:   Acute Leukemia, Chronic Myelogenous Leukemia, Myelodysplasia;   Chronic Lymphocyte Leukemia/Small Lymphocytic Lymphoma;   Lymphoma, B-Cell;   Lymphoma, Follicular;   Lymphoma, Large B-Cell, Diffuse
    Interventions:   Drug: Tacrolimus;   Drug: Methotrexate;   Drug: Bortezomib;   Drug: Maraviroc;   Drug: Mycophenolate mofetil;   Drug: Cyclophosphamide;   Drug: Tacrolimus (a)
    Sponsors:   Medical College of Wisconsin;   National Heart, Lung, and Blood Institute (NHLBI);   Blood and Marrow Transplant Clinical Trials Network;   National Cancer Institute (NCI)
    Not yet recruiting - verified August 2014

  • Conditions:   Diabetes;   Hyperlipidemia;   Hypertension;   Cardiovascular Disease
    Intervention:   Behavioral: CVRS Intervention
    Sponsor:   University of Iowa
    Not yet recruiting - verified August 2014

  • Conditions:   Urinary Tract Infection Complicated;   Acute Pyelonephritis;   Hospital Acquired Bacterial Pneumonia;   Ventilator-associated Bacterial Pneumonia;   Bacteremia
    Interventions:   Drug: Carbavance;   Drug: Best Available Therapy
    Sponsors:   Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company);   Department of Health and Human Services
    Not yet recruiting - verified July 2014

  • Conditions:   Urinary Tract Infection Complicated;   Acute Pyelonephritis
    Interventions:   Drug: Carbavance;   Drug: Piperacillin/tazobactam;   Drug: Levofloxacin oral
    Sponsors:   Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company);   Department of Health and Human Services
    Not yet recruiting - verified July 2014

  • Condition:   Rheumatoid Arthritis
    Interventions:   Drug: Tofacitinib;   Drug: Placebo
    Sponsor:   Pfizer
    Recruiting - verified August 2014

  • Condition:   HIV Infection
    Interventions:   Drug: Reformulated Raltegravir;   Drug: Raltegravir;   Drug: TRUVADA™;   Drug: Placebo to Reformulated Raltegravir;   Drug: Placebo to Raltegravir
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting - verified August 2014

  • Condition:   Infection, Human Immunodeficiency Virus
    Interventions:   Drug: ABC/DTG/3TC FDC;   Drug: Ongoing cART regimen
    Sponsors:   ViiV Healthcare;   PPD;   GlaxoSmithKline
    Recruiting - verified July 2014

  • Conditions:   Stage IA Fallopian Tube Cancer;   Stage IA Ovarian Epithelial Cancer;   Stage IA Primary Peritoneal Cavity Cancer;   Stage IB Fallopian Tube Cancer;   Stage IB Ovarian Epithelial Cancer;   Stage IB Primary Peritoneal Cavity Cancer;   Stage IC Fallopian Tube Cancer;   Stage IC Ovarian Epithelial Cancer;   Stage IC Primary Peritoneal Cavity Cancer;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Primary Peritoneal Cavity Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Primary Peritoneal Cavity Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Primary Peritoneal Cavity Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer
    Interventions:   Biological: DEC-205/NY-ESO-1 fusion protein CDX-1401;   Drug: poly ICLC;   Drug: IDO1 inhibitor INCB024360;   Other: pharmacological study;   Other: laboratory biomarker analysis
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Conditions:   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage I Squamous Cell Carcinoma of the Oropharynx;   Stage I Verrucous Carcinoma of the Oral Cavity;   Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage II Squamous Cell Carcinoma of the Oropharynx;   Stage II Verrucous Carcinoma of the Oral Cavity;   Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage III Verrucous Carcinoma of the Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Oropharynx;   Stage IVC Verrucous Carcinoma of the Oral Cavity
    Interventions:   Drug: HPPH;   Device: Light Infusion Therapy™;   Procedure: therapeutic conventional surgery
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Not yet recruiting - verified August 2014

  • Condition:   Moderate to Very Severe Chronic Obstructive Pulmonary Disease
    Interventions:   Drug: Benralizumab Arm A;   Drug: Benralizumab Arm B;   Drug: Placebo
    Sponsors:   AstraZeneca;   MedImmune LLC
    Recruiting - verified August 2014

  • Condition:   Chronic Obstructive Pulmonary Disease
    Interventions:   Drug: GS-5745;   Drug: Placebo to match GS-5745
    Sponsor:   Gilead Sciences
    Recruiting - verified August 2014

  • Condition:   Brain Ischemia
    Interventions:   Drug: alteplase [Activase];   Drug: alteplase placebo;   Drug: aspirin;   Drug: aspirin placebo
    Sponsor:   Genentech
    Recruiting - verified August 2014

  • Conditions:   Acute Myeloid Leukemia (AML);   Acute Lymphocytic Leukemia (ALL)
    Intervention:   Drug: CB-839
    Sponsor:   Calithera Biosciences, Inc
    Recruiting - verified August 2014

  • Conditions:   Anemia;   Renal Insufficiency, Chronic
    Interventions:   Drug: Molidustat (BAY85-3934);   Biological: Epoetin alfa/beta
    Sponsor:   Bayer
    Recruiting - verified August 2014

  • Conditions:   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Drug: dovitinib lactate;   Drug: gemcitabine hydrochloride;   Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Other: pharmacological study;   Other: laboratory biomarker analysis
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI);   Novartis
    Not yet recruiting - verified August 2014

  • Conditions:   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer
    Interventions:   Drug: IDO1 inhibitor INCB024360;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Condition:   Stage IV or Recurrent Non-Small Cell Lung Cancer
    Interventions:   Biological: Nivolumab;   Drug: Gemcitabine;   Drug: Cisplatin;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Pemetrexed
    Sponsor:   Bristol-Myers Squibb
    Recruiting - verified May 2014

  • Condition:   AML
    Interventions:   Drug: Quizartinib;   Drug: Salvage Chemotherapy
    Sponsor:   Ambit Biosciences Corporation
    Recruiting - verified August 2014

  • Conditions:   Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
    Interventions:   Drug: cytarabine;   Drug: omacetaxine mepesuccinate;   Drug: decitabine;   Other: laboratory biomarker analysis
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified July 2014

  • Condition:   Pneumonia
    Interventions:   Drug: TR-701 FA IV;   Drug: Linezolid
    Sponsor:   Cubist Pharmaceuticals
    Recruiting - verified August 2014

  • Condition:   Non-Small Cell Lung Cancer
    Interventions:   Drug: MPDL3280A;   Drug: docetaxel
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified August 2014

  • Condition:   Diabetes Mellitus, Type 1
    Interventions:   Drug: Intranasal Glucagon;   Drug: Glucagon
    Sponsors:   T1D Exchange Clinic Network Coordinating Center;   Locemia Solutions ULC
    Recruiting - verified August 2014

  • Conditions:   Diabetes Mellitus, Type 1;   Diabetes Mellitus, Type 2
    Interventions:   Drug: Intranasal Glucagon;   Drug: Glucagon
    Sponsors:   T1D Exchange Clinic Network Coordinating Center;   Locemia Solutions ULC
    Recruiting - verified August 2014

  • Condition:   Clostridium Difficile Associated Diarrhea
    Interventions:   Drug: Cadazolid;   Drug: vancomycin
    Sponsor:   Actelion
    Recruiting - verified August 2014

  • Condition:   Acute Myeloid Leukemia
    Intervention:   Drug: ASP2215
    Sponsors:   Astellas Pharma Inc;   Astellas Pharma Global Development, Inc.
    Recruiting - verified August 2014

  • Condition:   Kidney Transplantation Cytomegalovirus (CMV) Negative Recipients
    Interventions:   Biological: ASP0113;   Drug: Placebo
    Sponsors:   Astellas Pharma Inc;   Astellas Pharma Global Development, Inc.;   Vical
    Recruiting - verified August 2014

  • Condition:   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Drug: PI3K inhibitor BKM120;   Drug: gemcitabine hydrochloride;   Drug: cisplatin;   Other: pharmacological study;   Other: laboratory biomarker analysis
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI);   Novartis
    Not yet recruiting - verified August 2014

  • Condition:   Cardiovascular Disease
    Interventions:   Drug: PF-04950615;   Drug: Placebo
    Sponsor:   Pfizer
    Recruiting - verified August 2014

  • Condition:   Cardiovascular Disease
    Interventions:   Drug: PF-04950615;   Drug: Placebo
    Sponsor:   Pfizer
    Recruiting - verified August 2014

  • Conditions:   Anemia;   Renal Insufficiency, Chronic
    Interventions:   Drug: Molidustat (BAY 85-3934);   Biological: Epoetin alfa/beta
    Sponsor:   Bayer
    Recruiting - verified August 2014

  • Conditions:   COPD;   Chronic Obstructive Pulmonary Disease
    Interventions:   Drug: Aclidinium Bromide;   Drug: Placebo
    Sponsor:   Forest Laboratories
    Recruiting - verified July 2014

  • Conditions:   Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
    Interventions:   Drug: trametinib;   Drug: Akt inhibitor GSK2141795;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified July 2014

  • Conditions:   Pancreatic Neoplasms;   Digestive System Neoplasms;   Neoplasms by Site;   Neoplasms;   Endocrine Gland Neoplasms;   Pancreatic Diseases;   Digestive System Diseases;   Endocrine System Diseases;   Gemcitabine;   Antimetabolites, Antineoplastic
    Interventions:   Drug: nab-Paclitaxel 125 mg/m2;   Drug: gemcitabine 1000 mg/m2;   Drug: gemcitabine 1000 mg/m2
    Sponsor:   Celgene Corporation
    Recruiting - verified August 2014

  • Condition:   Heart Failure
    Interventions:   Drug: Vericiguat (BAY1021189) (1.25 mg);   Drug: Vericiguat (BAY1021189) (5 mg);   Drug: Placebo
    Sponsor:   Bayer
    Recruiting - verified August 2014

  • Condition:   Heart Failure
    Interventions:   Drug: Vericiguat (BAY1021189) (1.25 mg);   Drug: Vericiguat (BAY1021189) (5 mg);   Drug: Placebo
    Sponsor:   Bayer
    Recruiting - verified August 2014

  • Conditions:   Recurrent Non-small Cell Lung Cancer;   Squamous Cell Lung Cancer;   Stage III Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
    Interventions:   Drug: nintedanib;   Other: laboratory biomarker analysis
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI);   Boehringer Ingelheim
    Recruiting - verified July 2014

  • Condition:   Colorectal Neoplasms
    Interventions:   Drug: Regorafenib (Stivarga, BAY73-4506);   Drug: Placebo
    Sponsor:   Bayer
    Recruiting - verified August 2014

  • Conditions:   Agitation Associated With;   Alzheimer's Disease;   Alzheimer's Type;   Mental Disorder;   Nervous System Diseases
    Intervention:   Drug: Brexpiprazole, OPC-34712
    Sponsors:   Otsuka Pharmaceutical Development & Commercialization, Inc.;   H. Lundbeck A/S
    Recruiting - verified July 2014

  • Condition:   Infection, Human Immunodeficiency Virus
    Interventions:   Drug: Dolutegravir/abacavir/lamivudine FDC;   Drug: Atazanavir;   Drug: Ritonavir;   Drug: Tenofovir/emtricitabine FDC
    Sponsors:   ViiV Healthcare;   GlaxoSmithKline
    Recruiting - verified August 2014

  • Conditions:   Recurrent Renal Cell Cancer;   Stage IV Renal Cell Cancer
    Interventions:   Radiation: stereotactic body radiation therapy;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Conditions:   Heart Failure;   Coronary Artery Disease
    Interventions:   Drug: Rivaroxaban;   Drug: Placebo;   Other: Standard of care for heart failure and coronary artery disease
    Sponsor:   Janssen Research & Development, LLC
    Recruiting - verified August 2014

  • Condition:   Recurrent Small Cell Lung Cancer
    Interventions:   Drug: etirinotecan pegol (NKTR 102);   Other: pharmacogenomic studies;   Other: laboratory biomarker analysis
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI);   Nektar Therapeutics
    Recruiting - verified August 2014

  • Condition:   Smoker
    Interventions:   Other: Cigarettes;   Other: Snus
    Sponsor:   University of Minnesota - Clinical and Translational Science Institute
    Recruiting - verified August 2014

  • Condition:   Cystic Fibrosis
    Intervention:   Biological: pancrelipase
    Sponsors:   AbbVie;   Aptalis Pharma;   Janssen Research & Development, LLC
    Recruiting - verified August 2014

  • Conditions:   Recurrent Non-small Cell Lung Cancer;   Stage IIA Non-small Cell Lung Cancer;   Stage IIB Non-small Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer
    Interventions:   Drug: temoporfin;   Procedure: therapeutic conventional surgery;   Drug: photodynamic therapy;   Other: laboratory biomarker analysis;   Other: pharmacological study
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified July 2014

  • Condition:   Neoplasms
    Intervention:   Drug: Regorafenib (Stivarga, BAY73-4506)
    Sponsor:   Bayer
    Recruiting - verified August 2014

  • Conditions:   Newly Diagnosed;   Advanced Ovarian Cancer;   FIGO Stage III-IV;   BRCA Mutation;   Complete Response;   Partial Response;   First Line Platinum Chemotherapy
    Intervention:   Drug: Olaparib 300mg tablets
    Sponsors:   AstraZeneca;   Gynecologic Oncology Group (GOG);   Myriad Genetics - BRACAnalysis test for FDA Premarket Approval (PMA)
    Recruiting - verified August 2014

  • Condition:   Metastatic Pancreatic Cancer
    Interventions:   Drug: PEGPH20+nab-paclitaxel+gemcitabine;   Drug: nab-paclitaxel + gemcitabine
    Sponsor:   Halozyme Therapeutics
    Recruiting - verified January 2014

  • Conditions:   Clear Cell Renal Cell Carcinoma;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
    Interventions:   Drug: cabozantinib-s-malate;   Drug: sunitinib malate;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2014

  • Conditions:   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma
    Interventions:   Drug: lenalidomide;   Drug: ibrutinib;   Biological: rituximab;   Other: pharmacological study;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Condition:   Myelodysplastic Syndrome
    Interventions:   Drug: TL32711;   Drug: 5-Azacitidine
    Sponsor:   TetraLogic Pharmaceuticals
    Recruiting - verified August 2014

  • Condition:   Intracerebral Hemorrhage
    Intervention:   Drug: rt-PA
    Sponsors:   Johns Hopkins University;   Daniel Hanley;   National Institute of Neurological Disorders and Stroke (NINDS);   Genentech;   Emissary International LLC
    Recruiting - verified August 2014

  • Conditions:   Bone Metastases;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
    Interventions:   Radiation: radiation therapy;   Other: laboratory biomarker analysis
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI);   Dendreon
    Recruiting - verified August 2014

  • Condition:   Kidney Transplantation
    Interventions:   Drug: Belatacept;   Drug: Tacrolimus;   Drug: Cyclosporine
    Sponsor:   Bristol-Myers Squibb
    Recruiting - verified September 2013

  • Conditions:   Insular Thyroid Cancer;   Recurrent Thyroid Cancer;   Stage I Follicular Thyroid Cancer;   Stage I Papillary Thyroid Cancer;   Stage II Follicular Thyroid Cancer;   Stage II Papillary Thyroid Cancer;   Stage III Follicular Thyroid Cancer;   Stage III Papillary Thyroid Cancer;   Stage IVA Follicular Thyroid Cancer;   Stage IVA Papillary Thyroid Cancer;   Stage IVB Follicular Thyroid Cancer;   Stage IVB Papillary Thyroid Cancer;   Stage IVC Follicular Thyroid Cancer;   Stage IVC Papillary Thyroid Cancer
    Interventions:   Drug: cabozantinib-s-malate;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified July 2014

  • Conditions:   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
    Interventions:   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: idarubicin hydrochloride;   Drug: vorinostat;   Procedure: allogeneic hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Condition:   Pneumonia, Bacterial
    Interventions:   Drug: Amikacin Inhalation Solution (BAY41-6551);   Drug: Aerosolized Placebo
    Sponsors:   Bayer;   Nektar Therapeutics
    Recruiting - verified August 2014

  • Condition:   Intracranial Aneurysms
    Intervention:   Device: LVIS™ and LVIS™ Jr
    Sponsor:   Microvention-Terumo, Inc.
    Recruiting - verified August 2014

  • Conditions:   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult T-cell Leukemia/Lymphoma;   Stage I Childhood Hodgkin Lymphoma;   Stage II Adult Hodgkin Lymphoma;   Stage II Adult T-cell Leukemia/Lymphoma;   Stage II Childhood Hodgkin Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Childhood Hodgkin Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Childhood Hodgkin Lymphoma
    Interventions:   Other: Anthropometry;   Other: Serum Biomarkers;   Other: Diagnostic/symptom checklist;   Procedure: Echocardiogram;   Other: 6 minute walk test (6MWT);   Behavioral: Participant Questionnaires (ages >14 years only)
    Sponsors:   Children's Oncology Group;   The Leukemia and Lymphoma Society;   St. Baldrick's Foundation;   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Conditions:   Recurrent Non-small Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
    Interventions:   Procedure: therapeutic lymphadenectomy;   Radiation: stereotactic radiosurgery;   Other: quality-of-life assessment
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Condition:   Recurrent Neuroblastoma
    Interventions:   Drug: temozolomide;   Drug: irinotecan hydrochloride;   Drug: temsirolimus;   Biological: dinutuximab;   Biological: sargramostim;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Condition:   Cytomegalovirus Infections
    Interventions:   Drug: RG7667;   Drug: Placebo
    Sponsor:   Genentech
    Recruiting - verified August 2014

  • Conditions:   Ductal Breast Carcinoma in Situ;   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Invasive Ductal Breast Carcinoma;   Lobular Breast Carcinoma in Situ;   Progesterone Receptor-positive Breast Cancer;   Stage I Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer
    Interventions:   Procedure: therapeutic conventional surgery;   Radiation: radiation therapy;   Procedure: quality-of-life assessment
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Conditions:   Diabetes Mellitus, Non-Insulin-Dependent;   High Risk for Cardiovascular Event
    Interventions:   Drug: Dapagliflozin 10 mg;   Drug: Placebo tablet
    Sponsors:   AstraZeneca;   Bristol-Myers Squibb;   The TIMI Study Group;   Hadassah Medical Organization
    Recruiting - verified August 2014

  • Condition:   Indolent Non-Hodgkin's Lymphomas
    Interventions:   Drug: Idelalisib orally 150 mg BID;   Drug: Placebo orally 150 mg BID;   Drug: Rituximab IV 375 mg/m2 every 28 days for 4 cycles;   Drug: Bendamustine 90 mg/m2 for 2 consecutive days every 28 days for 4 cycles
    Sponsor:   Gilead Sciences
    Recruiting - verified August 2014

  • Conditions:   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage I Squamous Cell Carcinoma of the Oropharynx;   Stage I Verrucous Carcinoma of the Oral Cavity;   Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage II Squamous Cell Carcinoma of the Oropharynx;   Stage II Verrucous Carcinoma of the Oral Cavity;   Tongue Cancer
    Interventions:   Drug: photodynamic therapy;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis;   Drug: temoporfin
    Sponsors:   Roswell Park Cancer Institute;   National Institutes of Health (NIH);   Biolitec Pharmaceuticals, Ltd
    Recruiting - verified August 2014

  • Condition:   Nausea
    Interventions:   Device: Acupressure bands;   Other: Version 1 handout;   Behavioral: Version 1 MP3;   Other: Version 2 handout;   Behavioral: Version 2 MP3
    Sponsors:   University of Rochester;   National Center for Complementary and Alternative Medicine (NCCAM)
    Recruiting - verified August 2014

  • Condition:   Lymphocytic Leukemia, Chronic
    Interventions:   Drug: GDC-0199 (ABT-199);   Drug: Obinutuzumab
    Sponsor:   Genentech
    Recruiting - verified August 2014

  • Condition:   Breast Cancer
    Interventions:   Drug: anastrozole;   Drug: everolimus;   Drug: exemestane;   Drug: goserelin acetate;   Drug: letrozole;   Drug: leuprolide acetate;   Drug: tamoxifen citrate;   Other: placebo
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Conditions:   Clear Cell Renal Cell Carcinoma;   Stage IV Renal Cell Cancer
    Interventions:   Drug: pazopanib hydrochloride;   Biological: bevacizumab;   Other: pharmacological study;   Other: laboratory biomarker analysis
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI);   GlaxoSmithKline
    Recruiting - verified August 2014

  • Condition:   Cytomegalovirus Infections, Transplantation
    Intervention:  
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified August 2014

  • Condition:   Acute Coronary Syndrome
    Interventions:   Drug: alirocumab SAR236553 (REGN727);   Other: placebo
    Sponsors:   Sanofi;   Regeneron Pharmaceuticals
    Recruiting - verified August 2014

  • Conditions:   Lung Cancer;   Squamous Lung Dysplasia;   Tobacco Use Disorder
    Interventions:   Radiation: deuterated phenanthrene tetraol;   Other: pharmacological study;   Other: laboratory biomarker analysis
    Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   National Cancer Institute (NCI)
    Recruiting - verified January 2014

  • Condition:   Fibrosing Colonopathy in Patients With Cystic Fibrosis
    Interventions:   Biological: CREON;   Biological: ZENPEP;   Biological: ULTRESA;   Biological: PANCREAZE;   Biological: other non-sponsor pancreatic enzyme replacement therapy;   Other: No pancreatic enzyme replacement therapy
    Sponsors:   AbbVie;   AbbVie (prior sponsor, Abbott);   Aptalis Pharma;   Cystic Fibrosis Foundation;   Janssen Research & Development, LLC
    Recruiting - verified July 2014

  • Conditions:   Adult Acute Basophilic Leukemia;   Adult Acute Eosinophilic Leukemia;   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myelomonocytic Leukemia (M4);   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
    Interventions:   Drug: daunorubicin hydrochloride;   Drug: cytarabine;   Drug: decitabine;   Other: laboratory biomarker analysis;   Other: pharmacological study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Condition:   Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.
    Intervention:   Biological: Darbepoetin alfa
    Sponsor:   Amgen
    Recruiting - verified August 2014

  • Condition:   Hormone Receptor Positive Malignant Neoplasm of Breast
    Intervention:   Device: MammaPrint
    Sponsor:   Agendia
    Recruiting - verified July 2014

  • Conditions:   Acute Lymphocytic Leukemia;   Acute Myelogenous Leukemia;   Burkitt's Lymphoma;   Follicular Lymphoma;   Hodgkin Lymphoma;   Mantle Cell Lymphoma
    Interventions:   Biological: Haploidentical BMT;   Biological: Double Cord Blood Transplantation
    Sponsors:   Medical College of Wisconsin;   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   Blood and Marrow Transplant Clinical Trials Network
    Recruiting - verified August 2014

  • Conditions:   B-cell Childhood Acute Lymphoblastic Leukemia;   Childhood Diffuse Large Cell Lymphoma;   L3 Childhood Acute Lymphoblastic Leukemia;   Stage III Childhood Large Cell Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Biological: rituximab;   Drug: prednisone;   Drug: etoposide;   Drug: doxorubicin hydrochloride;   Drug: cytarabine;   Drug: vincristine sulfate;   Drug: cyclophosphamide;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: leucovorin calcium;   Drug: therapeutic hydrocortisone
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Condition:   Small Cell Lung Carcinoma
    Interventions:   Drug: Roniciclib (BAY 1000394);   Drug: Etoposide;   Drug: Cisplatin;   Drug: Carboplatin
    Sponsor:   Bayer
    Recruiting - verified August 2014

  • Conditions:   Neurofibromatosis Type 1;   Recurrent Childhood Pilocytic Astrocytoma;   Recurrent Childhood Visual Pathway Glioma
    Intervention:   Drug: lenalidomide
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Condition:   Acute Myeloid Leukemia
    Interventions:   Drug: PF-04449913;   Drug: Low dose ARA-C (LDAC);   Drug: PF-04449913;   Drug: Decitabine;   Drug: PF-04449913;   Drug: Daunorubicin;   Drug: Cytarabine;   Drug: Pf-04449913;   Drug: Daunorubicin;   Drug: Cytarabine;   Drug: PF-04449913;   Drug: Low dose ARA-C (LDAC)
    Sponsor:   Pfizer
    Recruiting - verified August 2014

  • Condition:   Ulcerative Colitis
    Interventions:   Drug: Mesalamine;   Drug: Prednisone;   Drug: Corticosteroids followed by mesalamine (Pentasa)
    Sponsors:   Connecticut Children's Medical Center;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting - verified August 2014

  • Conditions:   Adult Anaplastic Astrocytoma;   Adult Anaplastic Oligodendroglioma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Adult Primary Hepatocellular Carcinoma;   Chondrosarcoma;   Clear Cell Sarcoma of the Kidney;   Conjunctival Kaposi Sarcoma;   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   Hormone-resistant Prostate Cancer;   Limited Stage Small Cell Lung Cancer;   Localized Resectable Adult Primary Liver Cancer;   Male Breast Cancer;   Mast Cell Sarcoma;   Ovarian Sarcoma;   Recurrent Adult Brain Tumor;   Recurrent Adult Primary Liver Cancer;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Bladder Cancer;   Recurrent Breast Cancer;   Recurrent Colon Cancer;   Recurrent Esophageal Cancer;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Gastric Cancer;   Recurrent Kaposi Sarcoma;   Recurrent Melanoma;   Recurrent Non-small Cell Lung Cancer;   Recurrent Osteosarcoma;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Prostate Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Small Cell Lung Cancer;   Recurrent Uterine Sarcoma;   Small Intestine Leiomyosarcoma;   Stage I Colon Cancer;   Stage I Rectal Cancer;   Stage I Uterine Sarcoma;   Stage IA Breast Cancer;   Stage IA Gastric Cancer;   Stage IA Ovarian Epithelial Cancer;   Stage IA Ovarian Germ Cell Tumor;   Stage IB Breast Cancer;   Stage IB Gastric Cancer;   Stage IB Ovarian Epithelial Cancer;   Stage IB Ovarian Germ Cell Tumor;   Stage IC Ovarian Epithelial Cancer;   Stage IC Ovarian Germ Cell Tumor;   Stage II Breast Cancer;   Stage II Uterine Sarcoma;   Stage IIA Colon Cancer;   Stage IIA Gastric Cancer;   Stage IIA Non-small Cell Lung Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Ovarian Germ Cell Tumor;   Stage IIA Rectal Cancer;   Stage IIB Colon Cancer;   Stage IIB Esophageal Cancer;   Stage IIB Gastric Cancer;   Stage IIB Melanoma;   Stage IIB Non-small Cell Lung Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Ovarian Germ Cell Tumor;   Stage IIB Rectal Cancer;   Stage IIC Colon Cancer;   Stage IIC Melanoma;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Ovarian Germ Cell Tumor;   Stage IIC Rectal Cancer;   Stage III Uterine Sarcoma;   Stage IIIA Breast Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Esophageal Cancer;   Stage IIIA Gastric Cancer;   Stage IIIA Melanoma;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIA Rectal Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Esophageal Cancer;   Stage IIIB Gastric Cancer;   Stage IIIB Melanoma;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIB Rectal Cancer;   Stage IIIC Breast Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Esophageal Cancer;   Stage IIIC Gastric Cancer;   Stage IIIC Melanoma;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IIIC Rectal Cancer;   Stage IV Bladder Cancer;   Stage IV Esophageal Cancer;   Stage IV Gastric Cancer;   Stage IV Melanoma;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Stage IV Uterine Sarcoma;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Biological: DEC-205-NY-ESO-1 fusion protein vaccine;   Drug: sirolimus;   Other: laboratory biomarker analysis
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Conditions:   Fungal Infection;   Hematopoietic/Lymphoid Cancer
    Interventions:   Drug: caspofungin acetate;   Drug: fluconazole;   Drug: voriconazole;   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Conditions:   Long-term Effects Secondary to Cancer Therapy in Adults;   Squamous Cell Carcinoma of the Vulva;   Stage I Vulvar Cancer;   Stage II Vulvar Cancer;   Stage III Vulvar Cancer
    Interventions:   Other: clinical observation;   Procedure: sentinel lymph node biopsy;   Procedure: therapeutic conventional surgery;   Procedure: therapeutic lymphadenectomy;   Radiation: selective external radiation therapy
    Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Condition:   Non-Small Cell Lung Cancer
    Interventions:   Drug: GDC-0941;   Drug: carboplatin;   Drug: paclitaxel;   Drug: bevacizumab;   Drug: Placebo
    Sponsor:   Genentech
    Recruiting - verified August 2014

  • Conditions:   Contiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Mantle Cell Lymphoma
    Interventions:   Biological: ofatumumab;   Drug: cyclophosphamide;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: vincristine sulfate;   Drug: cytarabine;   Procedure: autologous hematopoietic stem cell transplantation;   Drug: methotrexate;   Other: laboratory biomarker analysis
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI);   National Comprehensive Cancer Network;   GlaxoSmithKline
    Recruiting - verified August 2014

  • Condition:   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Drug: PI3K inhibitor BKM120;   Drug: docetaxel;   Other: pharmacological study;   Other: questionnaire administration;   Other: laboratory biomarker analysis
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI);   Novartis
    Recruiting - verified August 2014

  • Conditions:   Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Salivary Gland Squamous Cell Carcinoma;   Stage III Salivary Gland Cancer;   Stage III Squamous Cell Carcinoma of the Hypopharynx;   Stage III Squamous Cell Carcinoma of the Larynx;   Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage III Squamous Cell Carcinoma of the Nasopharynx;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage III Verrucous Carcinoma of the Larynx;   Stage III Verrucous Carcinoma of the Oral Cavity;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IVA Salivary Gland Cancer;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Salivary Gland Cancer;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Verrucous Carcinoma of the Larynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Stage IVC Salivary Gland Cancer;   Stage IVC Squamous Cell Carcinoma of the Larynx;   Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Oropharynx;   Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Verrucous Carcinoma of the Larynx;   Stage IVC Verrucous Carcinoma of the Oral Cavity;   Tongue Cancer;   Untreated Metastatic Squamous Neck Cancer With Occult Primary
    Interventions:   Biological: cetuximab;   Biological: recombinant interleukin-12;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Condition:   Breast Cancer
    Intervention:  
    Sponsors:   City of Hope Medical Center;   National Institutes of Health (NIH);   National Institute on Aging (NIA)
    Recruiting - verified August 2014

  • Conditions:   Stroke;   Atrial Fibrillation
    Intervention:  
    Sponsor:   Boehringer Ingelheim
    Recruiting - verified August 2014

  • Condition:   Diabetes Mellitus, Type 2
    Interventions:   Drug: Placebo matching with Saxagliptin;   Drug: Metformin IR;   Drug: Metformin XR;   Drug: Saxagliptin;   Drug: Saxagliptin
    Sponsors:   Bristol-Myers Squibb;   AstraZeneca
    Recruiting - verified April 2014

  • Conditions:   Cervical Adenocarcinoma;   Cervical Adenosquamous Cell Carcinoma;   Cervical Squamous Cell Carcinoma;   Chemotherapeutic Agent Toxicity;   Cognitive/Functional Effects;   Psychosocial Effects of Cancer and Its Treatment;   Radiation Toxicity;   Sexuality and Reproductive Issues;   Stage IB Cervical Cancer;   Stage IIA Cervical Cancer;   Stage IIB Cervical Cancer;   Stage III Cervical Cancer;   Stage IVA Cervical Cancer
    Interventions:   Drug: cisplatin;   Drug: paclitaxel;   Drug: carboplatin;   Radiation: external beam radiation therapy;   Radiation: brachytherapy;   Other: quality-of-life assessment
    Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Condition:   Epilepsy
    Interventions:   Drug: USL261;   Drug: Placebo
    Sponsor:   Upsher-Smith Laboratories
    Recruiting - verified August 2014

  • Condition:   Acute Myeloid Leukemia
    Intervention:  
    Sponsors:   Center for International Blood and Marrow Transplant Research;   Resource for Clinical Investigations in Blood and Marrow Transplantation (RCI-BMT);   Pediatric Blood and Marrow Transplant Consortium;   St. Baldrick's Foundation;   Otsuka Pharmaceutical Development & Commercialization, Inc.
    Recruiting - verified August 2014

  • Condition:   Major Depressive Disorder
    Interventions:   Drug: Desvenlafaxine Succinate Sustained-Release;   Drug: Desvenlafaxine Succinate Sustained-Release;   Drug: Placebo
    Sponsor:   Pfizer
    Recruiting - verified August 2014

  • Condition:   Major Depressive Disorder
    Intervention:   Drug: DVS SR
    Sponsor:   Pfizer
    Recruiting - verified August 2014

  • Conditions:   Acute Leukemias of Ambiguous Lineage;   Bacterial Infection;   Diarrhea;   Fungal Infection;   Musculoskeletal Complications;   Neutropenia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
    Intervention:   Drug: levofloxacin
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Conditions:   Hematologic Malignancies;   Certain:;   Inherited Disorders of Metabolism;   Inherited Abnormalities of Erythrocyte Differentiation or Function;   Inherited Abnormalities of Platelets;   Disorders of the Immune System;   Histiocytic Disorders;   X-linked Adrenoleukodystrophy;   Primary Immunodeficiency Diseases;   Bone Marrow Failure;   Beta-thalassemia
    Intervention:   Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
    Sponsors:   Center for International Blood and Marrow Transplant Research;   National Marrow Donor Program
    Recruiting - verified August 2014

  • Conditions:   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-positive Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer
    Interventions:   Drug: doxorubicin hydrochloride;   Drug: docetaxel;   Drug: cyclophosphamide;   Biological: trastuzumab;   Drug: paclitaxel;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified July 2014

  • Conditions:   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
    Interventions:   Drug: systemic chemotherapy;   Drug: tamoxifen citrate;   Drug: anastrozole;   Drug: exemestane;   Drug: letrozole;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified March 2014

  • Conditions:   Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
    Interventions:   Biological: ziv-aflibercept;   Biological: aldesleukin;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Conditions:   Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia
    Interventions:   Biological: alemtuzumab;   Drug: dasatinib;   Drug: daunorubicin hydrochloride;   Drug: fludarabine phosphate;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: in vitro-treated peripheral blood stem cell transplantation;   Drug: dexamethasone;   Drug: cyclophosphamide;   Biological: filgrastim;   Biological: pegfilgrastim;   Drug: methotrexate;   Drug: leucovorin calcium;   Drug: melphalan;   Drug: tacrolimus;   Drug: etoposide phosphate;   Drug: cytarabine;   Drug: mercaptopurine;   Drug: vincristine sulfate;   Other: pharmacological study;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified July 2014

  • Conditions:   MDS;   CMML;   AML
    Interventions:   Drug: SGI-110;   Drug: SGI-110
    Sponsor:   Astex Pharmaceuticals
    Recruiting - verified August 2014

  • Conditions:   Advanced Solid Tumors;   Advanced Recurrent Ovarian Tumors
    Interventions:   Drug: MEDI3617;   Drug: MEDI3617 + Bev Q3W Dose Escalation;   Drug: MEDI3617 + Bev Q2W Dose Escalation;   Drug: Optional Dose Expansion;   Drug: MEDI3617 + Weekly Pax Dose Escalation;   Drug: MEDI3617 + Pax & Carbo Q3W Dos Esc;   Drug: MEDI3617 + Gem & Carbo Q3W Dos Esc;   Drug: Advanced Recurrent Ovarian Tumors
    Sponsor:   MedImmune LLC
    Recruiting - verified August 2014

  • Conditions:   Adult Supratentorial Primitive Neuroectodermal Tumor (PNET);   Childhood Supratentorial Primitive Neuroectodermal Tumor;   Ewing Sarcoma of Bone;   Extraosseous Ewing Sarcoma;   Extraosseous Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Peripheral Primitive Neuroectodermal Tumor of the Kidney;   Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
    Interventions:   Drug: vincristine sulfate;   Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Drug: ifosfamide;   Drug: etoposide;   Drug: topotecan hydrochloride;   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Conditions:   Prostate Neoplasms;   Genital Neoplasms, Male;   Urogenital Neoplasms;   Genital Diseases, Male
    Intervention:   Drug: Abiraterone Acetate
    Sponsor:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
    Recruiting - verified August 2014

  • Conditions:   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Pineoblastoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor
    Interventions:   Drug: temozolomide;   Drug: irinotecan hydrochloride;   Biological: bevacizumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified March 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Lenalidomide;   Drug: Bortezomib;   Drug: Dexamethasone;   Procedure: Autologous Stem Cell Transplant
    Sponsors:   Dana-Farber Cancer Institute;   Paul G. Richardson, MD;   Celgene Corporation;   Millennium Pharmaceuticals, Inc.;   Massachusetts General Hospital;   Cape Cod Healthcare;   Beth Israel Deaconess Medical Center;   Emory University;   University of Michigan;   Fox Chase Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Fred Hutchinson Cancer Research Center;   Barbara Ann Karmanos Cancer Institute;   Duke University;   University of California, San Francisco;   University of Chicago;   M.D. Anderson Cancer Center;   UNC Lineberger Comprehensive Cancer Center;   Roswell Park Cancer Institute;   Stanford University;   University of Mississippi Medical Center;   Mount Sinai School of Medicine;   Wake Forest Baptist Health;   University of Arizona;   OHSU Knight Cancer Institute;   Eastern Maine Medical Center;   University of California, San Diego;   University of Alabama at Birmingham;   University of Pittsburgh;   Ochsner Health System;   University of Texas Southwestern Medical Center;   State University of New York - Downstate Medical Center;   Newton-Wellesley Hospital;   Baylor College of Medicine;   Beckman Research Institute;   University of Florida;   North Shore Long Island Jewish Health System;   H. Lee Moffitt Cancer Center and Research Institute;   Vanderbilt University;   Ohio State University;   Huntsman Cancer Institute;   Columbia University
    Recruiting - verified August 2014

  • Condition:   Type 2 Diabetes
    Interventions:   Drug: Saxagliptin;   Drug: Placebo (Saxagliptin);   Drug: Metformin IR;   Drug: Placebo (Metformin);   Drug: Metformin (Active Rescue)
    Sponsors:   Bristol-Myers Squibb;   AstraZeneca
    Recruiting - verified April 2014

  • Conditions:   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Other: laboratory biomarker analysis;   Other: cytology specimen collection procedure
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Conditions:   Recurrent Bladder Cancer;   Stage 0 Bladder Cancer;   Stage I Bladder Cancer;   Stage II Bladder Cancer;   Transitional Cell Carcinoma of the Bladder
    Interventions:   Drug: broccoli sprout extract;   Other: laboratory biomarker analysis
    Sponsors:   Roswell Park Cancer Institute;   Johns Hopkins University
    Recruiting - verified August 2014

  • Conditions:   Childhood Infratentorial Ependymoma;   Childhood Supratentorial Ependymoma;   Newly Diagnosed Childhood Ependymoma
    Interventions:   Drug: liposomal vincristine sulfate;   Other: clinical observation;   Radiation: 3-dimensional conformal radiation therapy;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: cisplatin;   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Condition:   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Dietary Supplement: calcitriol;   Drug: cisplatin;   Drug: gemcitabine hydrochloride;   Other: pharmacological study
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Conditions:   Clear Cell Renal Cell Carcinoma;   Stage IV Renal Cell Cancer
    Interventions:   Drug: entinostat;   Biological: aldesleukin;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Radiation: fludeoxyglucose F 18;   Procedure: positron emission tomography;   Procedure: computed tomography
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified July 2014

  • Conditions:   Lymphoma;   Lymphoproliferative Disorder
    Interventions:   Other: biologic sample preservation procedure;   Other: informational intervention
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Conditions:   Childhood Hepatoblastoma;   Stage I Childhood Liver Cancer;   Stage II Childhood Liver Cancer;   Stage III Childhood Liver Cancer;   Stage IV Childhood Liver Cancer
    Interventions:   Procedure: therapeutic conventional surgery;   Drug: cisplatin;   Drug: fluorouracil;   Drug: vincristine sulfate;   Drug: doxorubicin hydrochloride;   Drug: irinotecan hydrochloride;   Procedure: liver transplantation;   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Conditions:   Spinal Cord Stimulation;   Deep Brain Stimulation;   Drug Infusion (Implantable Pumps);   Sacral Nerve Stimulation
    Intervention:   Device: Various
    Sponsor:   MedtronicNeuro
    Recruiting - verified July 2014

  • Condition:   Leukemia
    Interventions:   Genetic: DNA analysis;   Genetic: RNA analysis;   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization;   Genetic: gene expression analysis;   Genetic: microarray analysis;   Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Other: pharmacological study
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Conditions:   Adult Rhabdomyosarcoma;   Childhood Desmoplastic Small Round Cell Tumor;   Chordoma;   Desmoid Tumor;   Metastatic Childhood Soft Tissue Sarcoma;   Nonmetastatic Childhood Soft Tissue Sarcoma;   Previously Treated Childhood Rhabdomyosarcoma;   Previously Untreated Childhood Rhabdomyosarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Stage I Adult Soft Tissue Sarcoma;   Stage II Adult Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
    Interventions:   Other: biologic sample preservation procedure;   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Conditions:   Childhood Atypical Teratoid/Rhabdoid Tumor;   Childhood Central Nervous System Germ Cell Tumor;   Childhood Choroid Plexus Tumor;   Childhood Craniopharyngioma;   Childhood Grade I Meningioma;   Childhood Grade II Meningioma;   Childhood Grade III Meningioma;   Childhood High-grade Cerebral Astrocytoma;   Childhood Infratentorial Ependymoma;   Childhood Low-grade Cerebral Astrocytoma;   Childhood Oligodendroglioma;   Childhood Supratentorial Ependymoma;   Newly Diagnosed Childhood Ependymoma;   Recurrent Childhood Cerebellar Astrocytoma;   Recurrent Childhood Cerebral Astrocytoma;   Recurrent Childhood Ependymoma;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor;   Recurrent Childhood Visual Pathway and Hypothalamic Glioma;   Recurrent Childhood Visual Pathway Glioma
    Intervention:   Other: cytology specimen collection procedure
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Conditions:   Leukemia;   Lymphoma
    Intervention:   Other: biologic sample preservation procedure
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Condition:   Sarcoma
    Intervention:   Other: biologic sample preservation procedure
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Condition:   Lymphoma
    Intervention:   Other: biologic sample preservation procedure
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Conditions:   Acute Undifferentiated Leukemia;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Childhood Acute Lymphoblastic Leukemia;   Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies;   Childhood Chronic Myelogenous Leukemia;   Chronic Lymphocytic Leukemia;   Hairy Cell Leukemia;   Juvenile Myelomonocytic Leukemia;   Mast Cell Leukemia;   Neoplasm of Uncertain Malignant Potential;   Prolymphocytic Leukemia;   Secondary Acute Myeloid Leukemia;   T-cell Large Granular Lymphocyte Leukemia;   Unspecified Childhood Solid Tumor, Protocol Specific
    Intervention:   Other: cytology specimen collection procedure
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Conditions:   Askin Tumor;   Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
    Intervention:   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Conditions:   Clear Cell Sarcoma of the Kidney;   Congenital Mesoblastic Nephroma;   Diffuse Hyperplastic Perilobar Nephroblastomatosis;   Rhabdoid Tumor of the Kidney;   Stage I Renal Cell Cancer;   Stage I Wilms Tumor;   Stage II Renal Cell Cancer;   Stage II Wilms Tumor;   Stage III Renal Cell Cancer;   Stage III Wilms Tumor;   Stage IV Renal Cell Cancer;   Stage IV Wilms Tumor;   Stage V Wilms Tumor
    Interventions:   Other: laboratory biomarker analysis;   Other: cytology specimen collection procedure
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Conditions:   Non-Small Cell Lung Cancer;   Anemia;   Cancer;   Lung Cancer
    Interventions:   Drug: darbepoetin alfa 500 mcg Q3W;   Drug: placebo
    Sponsor:   Amgen
    Recruiting - verified July 2014

  • Condition:   B-cell Chronic Lymphocytic Leukemia
    Interventions:   Drug: Lenalidomide;   Drug: Placebo
    Sponsor:   Celgene Corporation
    Recruiting - verified August 2014

  • Conditions:   Chemotherapeutic Agent Toxicity;   Childhood Cancer;   Cognitive/Functional Effects;   Neurotoxicity;   Psychosocial Effects of Cancer and Its Treatment;   Radiation Toxicity
    Interventions:   Procedure: psychosocial assessment and care;   Procedure: cognitive assessment;   Other: quality-of-life assessment;   Other: questionnaire administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Condition:   Ductal Breast Carcinoma in Situ
    Interventions:   Biological: trastuzumab;   Radiation: whole breast irradiation;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Acute Myeloid Leukemia/Transient Myeloproliferative Disorder;   Acute Undifferentiated Leukemia;   Angioimmunoblastic T-cell Lymphoma;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Grade III Lymphomatoid Granulomatosis;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Essential Thrombocythemia;   Extramedullary Plasmacytoma;   Intraocular Lymphoma;   Isolated Plasmacytoma of Bone;   Juvenile Myelomonocytic Leukemia;   Long-term Effects Secondary to Cancer Therapy in Children;   Mast Cell Leukemia;   Meningeal Chronic Myelogenous Leukemia;   Monoclonal Gammopathy of Undetermined Significance;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Polycythemia Vera;   Post-transplant Lymphoproliferative Disorder;   Primary Central Nervous System Hodgkin Lymphoma;   Primary Central Nervous System Non-Hodgkin Lymphoma;   Primary Myelofibrosis;   Primary Systemic Amyloidosis;   Progressive Hairy Cell Leukemia, Initial Treatment;   Prolymphocytic Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Stage 0 Chronic Lymphocytic Leukemia;   Stage I Childhood Anaplastic Large Cell Lymphoma;   Stage I Childhood Hodgkin Lymphoma;   Stage I Childhood Large Cell Lymphoma;   Stage I Childhood Lymphoblastic Lymphoma;   Stage I Childhood Small Noncleaved Cell Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Multiple Myeloma;   Stage I Mycosis Fungoides/Sezary Syndrome;   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage II Childhood Hodgkin Lymphoma;   Stage II Childhood Large Cell Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Childhood Small Noncleaved Cell Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Multiple Myeloma;   Stage II Mycosis Fungoides/Sezary Syndrome;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Hodgkin Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Childhood Small Noncleaved Cell Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Multiple Myeloma;   Stage III Mycosis Fungoides/Sezary Syndrome;   Stage IV Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Hodgkin Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Childhood Small Noncleaved Cell Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Mycosis Fungoides/Sezary Syndrome;   T-cell Large Granular Lymphocyte Leukemia;   Unspecified Childhood Solid Tumor, Protocol Specific;   Untreated Childhood Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies;   Untreated Hairy Cell Leukemia;   Waldenström Macroglobulinemia
    Interventions:   Other: survey administration;   Procedure: assessment of therapy complications;   Procedure: long-term screening;   Procedure: study of high risk factors
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Condition:   Human Immunodeficiency Virus
    Interventions:   Drug: Maraviroc along with an optimized background antiretroviral drug regimen;   Drug: Optimized background antiretroviral drug regimen without maraviroc
    Sponsors:   ViiV Healthcare;   Pfizer
    Recruiting - verified August 2014

  • Conditions:   Crohn's Disease;   Ulcerative Colitis;   Indeterminate Colitis;   Inflammatory Bowel Diseases
    Interventions:   Biological: Anti TNF therapy including infliximab;   Drug: No Biologics
    Sponsor:   Janssen Biotech, Inc.
    Recruiting - verified August 2014

  • Conditions:   Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Salivary Gland Squamous Cell Carcinoma;   Stage IV Salivary Gland Cancer;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IVA Salivary Gland Cancer;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Salivary Gland Cancer;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Verrucous Carcinoma of the Larynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Stage IVC Salivary Gland Cancer;   Stage IVC Squamous Cell Carcinoma of the Larynx;   Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Oropharynx;   Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Verrucous Carcinoma of the Larynx;   Stage IVC Verrucous Carcinoma of the Oral Cavity;   Tongue Cancer;   Untreated Metastatic Squamous Neck Cancer With Occult Primary
    Interventions:   Drug: docetaxel;   Drug: cisplatin;   Drug: carboplatin;   Drug: fluorouracil;   Biological: bevacizumab;   Other: laboratory biomarker analysis;   Other: cytology specimen collection procedure
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Condition:   Prostate Cancer
    Interventions:   Drug: bicalutamide;   Drug: flutamide;   Radiation: radiation therapy
    Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   NRG Oncology Foundation, Inc.
    Recruiting - verified July 2014

  • Condition:   Epilepsies, Partial
    Interventions:   Drug: Lyrica (pregabalin);   Drug: placebo
    Sponsor:   Pfizer
    Recruiting - verified August 2014

  • Conditions:   Cancer Survivor;   Cardiovascular Complications;   Hematopoietic/Lymphoid Cancer;   Unspecified Childhood Solid Tumor, Protocol Specific
    Interventions:   Other: questionnaire administration;   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Conditions:   Disseminated Neuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Regional Neuroblastoma;   Stage 4S Neuroblastoma
    Interventions:   Drug: isotretinoin;   Biological: sargramostim;   Biological: dinutuximab;   Biological: aldesleukin;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment;   Other: pharmacological study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2014

PaidClinicalTrials.orgPaidClinicalTrials.org